Clinical Trial Update: Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating magrolimab and cetuximab with either pembrolizumab or docetaxel for recurrent/metastatic head and neck squamous cell carcinoma was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)
• Magrolimab (magrolimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head Neck, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2025-10-22